Yahoo Finance Eton Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations
Eton Pharmaceuticals (NASDAQ:ETON) First Quarter 2024 Results
Key Financial Results
Revenue: US$7.97m (up 50% from 1Q 2023).
Net loss: US$811.0k (loss narrowed by 70% from 1Q 2023).
US$0.031 loss per share (improved from US$0.10 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Eton Pharmaceuticals EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 33%.
Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 7.5% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for Eton Pharmaceuticals that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
